NCT00435578TerminatedPhase 2
An Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of Glufosfamide in the Treatment of Patients With Recurrent Sensitive Small Cell Lung Carcinoma
Threshold Pharmaceuticals3 sites in 1 country50 target enrollmentStarted: February 1, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 2
- Status
- Terminated
- Sponsor
- Threshold Pharmaceuticals
- Enrollment
- 50
- Locations
- 3
Study Overview
Brief Summary
The primary objectives of this study are:
- To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive small cell lung cancer (SCLC) as measured by objective response rate
- To evaluate the safety of glufosfamide in subjects with extensive recurrent sensitive SCLC
The secondary objectives are:
- To evaluate the efficacy of glufosfamide in subjects with extensive recurrent sensitive SCLC as measured by duration of response, progression-free survival and overall survival
- To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard (IPM)
The exploratory objectives of this trial are:
- To evaluate the effect of glufosfamide on lung cancer symptoms
- To evaluate the role of tumor cell glucose transporter expression on the efficacy of glufosfamide
Study Design
- Study Type
- Interventional
- Allocation
- Non Randomized
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •At least 18 years of age
- •Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB/IEC
- •Documented extensive SCLC with progression occurring at least 60 days after completion of first-line therapy (sensitive disease)
- •Measurable disease by RECIST criteria (at least one target lesion; no target lesion may have received radiotherapy within 6 weeks of study start)
- •A minimum of 21 days between prior radiation therapy, immunotherapy, or other anti-tumor therapy and study entry
- •Recovered from reversible toxicities of prior therapy
- •Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2
- •Hemoglobin ≥ 9.0 g/dL, ANC ≥ 1,500/µL, platelets ≥ 100,000/µL
- •Total bilirubin ≤ 1.5-fold ULN
- •AST/ALT ≤ 2.5-fold ULN (≤ 5-fold ULN if liver metastases)
- •Creatinine clearance ≥ 60 mL/min (calculated by Cockcroft-Gault formula)
- •All women of childbearing potential and all men must agree to use effective means of contraception (surgical sterilization or the use of barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel or an IUD) from entry into the study through 6 months after the last dose
Exclusion Criteria
- •More than one previous chemotherapy regimen
- •Concomitant or planned hormonal therapy, radiation therapy, biologic therapy, chemotherapy or other systemic antitumor therapy for SCLC other than protocol therapy
- •Limited stage SCLC (defined as confined to one hemithorax including ipsilateral supraclavicular lymph nodes and excluding pleural effusion)
- •Symptomatic brain metastases requiring corticosteroids
- •Active clinically significant infection requiring antibiotics
- •Known HIV positive or active hepatitis B or C
- •Recent (one year) history or symptoms of cardiovascular disease (NYHA Class 2, 3, or 4), particularly coronary artery disease, arrhythmias or conduction defects with risk of cardiovascular instability, uncontrolled hypertension, clinically significant pericardial effusion, congestive heart failure, or stroke
- •Other active malignancies (other than treated non-melanoma skin cancer or treated in situ cancer) within the past 5 years
- •Major surgery within 28 days of the start of study treatment, without complete recovery
- •Females who are pregnant or breast-feeding
- •Participation in an investigational drug or device study within 28 days of the first day of dosing on this study
- •Concomitant disease or condition that could interfere with the conduct of the study, or that, in the opinion of the investigator, could pose an unacceptable risk to the subject in this study.
- •Unwillingness or inability to comply with the study protocol for any other reason
Investigators
Study Sites (3)
Loading locations...
Similar Trials
Completed
Phase 2
Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue SarcomaSoft Tissue SarcomaNCT00441467Eleison Pharmaceuticals LLC.22
Completed
Phase 3
Study of the Efficacy and Safety of Glufosfamide Compared With Best Supportive Care in Metastatic Pancreatic CancerPancreatic CancerNCT00099294Threshold Pharmaceuticals300
Completed
Phase 2
Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.Non Small Cell Lung CancerNCT00160043Bayer112
Completed
Phase 2
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate CancerCastration-resistant Prostate CancerCRPCNCT02012920Innocrin Pharmaceutical200
Not yet recruiting
Phase 1
A Study in Subjects With Human Papillomavirus 16 or 18 Associated Cervical Intraepithelial Neoplasia Grade 2 or 3Human Papillomavirus Associated Intraepithelial NeoplasiaHuman Papillomavirus Type 18 InfectionCervical Intraepithelial Neoplasia Grade 2/3Human Papillomavirus Type 16 InfectionNCT06273553RinuaGene Biotechnology Co., Ltd.39